Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model
NCT01332188
·
clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
COMPLETED
Status
101
Enrollment
INDUSTRY
Sponsor class
Conditions
Allergic Conjunctivitis
Interventions
DRUG:
AC-170 0.05%
DRUG:
AC-170 0.1%
DRUG:
AC-170 0.24%
DRUG:
AC-170 0%
Sponsor
Aciex Therapeutics, Inc.